Form 4: RA Capital Management Boosts Stake in Tyra Biosciences with Over $12 Million in Insider Purchases

RA Capital Management, a significant shareholder and director of Tyra Biosciences, Inc., has substantially increased its beneficial ownership through recent open market purchases of common stock.

Summary

• RA Capital Management, L.P., along with its affiliated funds (RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P.) and managing members (Peter Kolchinsky and Rajeev Shah), reported significant purchases of Tyra Biosciences, Inc. (TYRA) common stock.
• On June 4, 2025, 997,864 shares of common stock were acquired at a weighted average price of $9.63 per share, with prices ranging from $9.32 to $10.15.
• On June 5, 2025, an additional 213,334 shares of common stock were acquired at a weighted average price of $10.04 per share, with prices ranging from $9.48 to $10.18.
• These transactions represent a total acquisition of 1,211,198 shares over two days, amounting to approximately $12.08 million based on weighted average prices.
• Following these transactions, the RA Capital Healthcare Fund, L.P. directly holds 9,909,154 shares.
• The RA Capital Nexus Fund, L.P. directly holds 1,496,613 shares.
• A separately managed account holds 442,721 shares.
• The total indirect beneficial ownership by RA Capital Management and its affiliates, including the recent purchases, stands at 11,848,488 shares of common stock.
• RA Capital Management, L.P., its general partner, and its managing members (Dr. Kolchinsky and Mr. Shah) disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to substantial insider buying by a key institutional investor and director, signaling strong confidence in the company's future performance and valuation.

Positives

• Significant insider buying by a major institutional investor (RA Capital Management) indicates strong confidence in Tyra Biosciences' future prospects.
• The purchases were made at varying price points, suggesting a strategic accumulation of shares rather than a single opportunistic buy.
• The substantial increase in beneficial ownership by a 10% owner and director signals alignment of interests between the investor and other shareholders.

Management Comments

• RA Capital Management, L.P., RA Capital Management GP, LLC, Dr. Peter Kolchinsky, and Mr. Rajeev Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Industry Context

This insider buying by RA Capital Management, a prominent healthcare-focused investment firm, in Tyra Biosciences, a biotechnology company, suggests a positive outlook on the company's pipeline or strategic direction within the competitive biotech sector. Such significant investment by a specialized fund often signals a belief in the long-term value and potential of the company's therapeutic candidates or technology.

Related Party Transactions

• RA Capital Management, L.P., an entity with director representation and a 10% owner stake in Tyra Biosciences, Inc., purchased 1,211,198 shares of common stock through its affiliated funds and accounts on June 4 and June 5, 2025.

Stakeholder Impact

• Shareholders: The significant insider buying by a major investor and director could instill greater confidence in the company's stock and future performance, potentially leading to positive market perception and share price appreciation.

Key Dates

Recommendation

Keywords

Tyra Biosciences, TYRA, RA Capital Management, Insider Buying, Form 4, Beneficial Ownership, Common Stock, Investment, Biotechnology, Healthcare Investment